The COSMIQ Blog
Articles tagged “cancer education” · Clear filter
Early SynKIR-310 Data Put Safety Questions at Center of ASH Talk
Verismo Therapeutics says its first-in-human SynKIR-310 study reported responses in a small early-phase cohort without reported CRS or ICANS at the first two dose levels. The December ASH presentation is expected to add data from a third cohort.
Learn anything, free.
COSMIQ is a free, voice-driven AI tutor for every learner. No credit card, ever.
Start learning free →